Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as it ameliorates the motor symptoms. However, it does not affect the progression of the disease and its long-term use triggers severe complications. There are no bona fide biomarkers for monitoring the patients’ response to LevoDopa and predicting the efficacy of levodopa treatment. Here, we have combined qPCR microRNA array screening with analysis of validated miRs in naïve versus Levodopa-treated PD patients. We have identified plasma miR-19b as a possible biomarker for LevoDopa therapy and validated this result in human differentiated dopaminergic neurons exposed to LevoDopa. In silico analysis suggests that the LevoDopa-induced miR-19b regulates ubiquitin-mediated proteolysis.

中文翻译：

---

血浆 hsa-mir-19b 是潜在的左旋多巴治疗标志物

帕金森病 (PD) 是老年人中第二常见的神经退行性疾病，其诊断和预后主要基于临床症状。左旋多巴替代疗法是 PD 的金标准疗法，因为它可以改善运动症状。然而，它不会影响疾病的进展，长期使用会引发严重的并发症。没有真正的生物标志物可用于监测患者对左旋多巴的反应并预测左旋多巴治疗的疗效。在这里，我们将 qPCR microRNA 阵列筛选与在初始与左旋多巴治疗的 PD 患者中经过验证的 miR 的分析相结合。我们已将血浆 miR-19b 鉴定为左旋多巴治疗的可能生物标志物，并在暴露于左旋多巴的人类分化多巴胺能神经元中验证了这一结果。